English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Regulation of MRE11A by UBQLN4 leads to cisplatin resistance in patients with esophageal squamous cell carcinoma

Murakami, T., Shoji, Y., Nishi, T., Chang, S. C., Jachimowicz, R. D., Hoshimoto, S., et al. (2021). Regulation of MRE11A by UBQLN4 leads to cisplatin resistance in patients with esophageal squamous cell carcinoma. Mol Oncol, 15(4), 1069-1087. doi:10.1002/1878-0261.12929.

Item is

Files

show Files

Locators

show
hide
Description:
-
OA-Status:
Not specified

Creators

show
hide
 Creators:
Murakami, T., Author
Shoji, Y., Author
Nishi, T., Author
Chang, S. C., Author
Jachimowicz, R. D.1, Author           
Hoshimoto, S., Author
Ono, S., Author
Shiloh, Y., Author
Takeuchi, H., Author
Kitagawa, Y., Author
Hoon, D. S. B., Author
Bustos, M. A., Author
Affiliations:
1Jachimowicz – Mechanisms of DNA Repair, Max Planck Research Groups, Max Planck Institute for Biology of Ageing, Max Planck Society, ou_3394003              

Content

show
hide
Free keywords: Mre11 chemoresistance esophageal cancer neoadjuvant chemotherapy ubiquilin-4
 Abstract: Resistance to standard cisplatin-based chemotherapies leads to worse survival outcomes for patients with esophageal squamous cell carcinoma (ESCC). Therefore, there is an urgent need to understand the aberrant mechanisms driving resistance in ESCC tumors. We hypothesized that ubiquilin-4 (UBQLN4), a protein that targets ubiquitinated proteins to the proteasome, regulates the expression of Meiotic Recombination 11 Homolog A (MRE11A), a critical component of the MRN complex and DNA damage repair pathways. Initially, immunohistochemistry analysis was conducted in specimens from patients with ESCC (n = 120). In endoscopic core ESCC biopsies taken from 61 patients who underwent neoadjuvant chemotherapy (NAC) (5-fluorouracil and cisplatin), low MRE11A and high UBQLN4 protein levels were associated with reduced pathological response to NAC (P < 0.001 and P < 0.001, respectively). Multivariable analysis of surgically resected ESCC tissues from 59 patients revealed low MRE11A and high UBLQN4 expression as independent factors that can predict shorter overall survival [P = 0.01, hazard ratio (HR) = 5.11, 95% confidence interval (CI), 1.45-18.03; P = 0.02, HR = 3.74, 95% CI, 1.19-11.76, respectively]. Suppression of MRE11A expression was associated with cisplatin resistance in ESCC cell lines. Additionally, MRE11A was found to be ubiquitinated after cisplatin treatment. We observed an amplification of UBQLN4 gene copy numbers and an increase in UBQLN4 protein levels in ESCC tissues. Binding of UBQLN4 to ubiquitinated-MRE11A increased MRE11A degradation, thereby regulating MRE11A protein levels following DNA damage and promoting cisplatin resistance. In summary, MRE11A and UBQLN4 protein levels can serve as predictors for NAC response and as prognostic markers in ESCC patients.

Details

show
hide
Language(s):
 Dates: 2021-02-202021-02-20
 Publication Status: Issued
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: Other: 33605536
DOI: 10.1002/1878-0261.12929
ISSN: 1878-0261 (Electronic)1574-7891 (Linking)
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Mol Oncol
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 15 (4) Sequence Number: - Start / End Page: 1069 - 1087 Identifier: -